Hansa Biopharma AB (OSTO:HNSA) Receivables Turnover : 0.75 (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Hansa Biopharma AB's Revenue for the three months ended in Mar. 2024 was kr56.0 Mil. Hansa Biopharma AB's average Accounts Receivable for the three months ended in Mar. 2024 was kr74.4 Mil. Hence, Hansa Biopharma AB's Receivables Turnover for the three months ended in Mar. 2024 was 0.75.

Hansa Biopharma AB Receivables Turnover Historical Data

The historical data trend for Hansa Biopharma AB's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Receivables Turnover Chart

Hansa Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

11.60

19.30

6.90

17.10

3.17

Hansa Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Receivables Turnover	Get a 7-Day Free Trial															0.87	0.62	0.34	0.71	0.75

Competitive Comparison of Hansa Biopharma AB's Receivables Turnover

For the Biotechnology subindustry, Hansa Biopharma AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hansa Biopharma AB's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Receivables Turnover falls into.

Hansa Biopharma AB Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Hansa Biopharma AB's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	134.094	/ (	(8.36	+	76.266)	/	2 )
=	134.094	/	42.313
=	3.17

Hansa Biopharma AB's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

	Receivables Turnover (Q: Mar. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Mar. 2024 ))	/	count )
=	55.981	/ (	(76.266	+	72.596)	/	2 )
=	55.981	/	74.431
=	0.75

Hansa Biopharma AB (OSTO:HNSA) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Hansa Biopharma AB Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansa Biopharma AB (OSTO:HNSA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

HNSBF:USA 0RC7:UK 24H:Germany

Address

Scheelevagen 22, Lund, SWE, 223 63

Website

https://www.hansabiopharma.com

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines